Mylanta (probably containing aluminium/magnesium hydroxide) reduces the bioa- vailability of fosinopril
by about one-third.
The manufacturers suggest separating its dosing from that of antacids
by at least 2 hours. Antacids
are said to reduce the bioavailability of a number of ACE inhibitors
but this seems unlikely to be clinically important (except perhaps in the case of fosinopril
, see above).
Several manufacturers of ACE inhibitors
warn that antacids
may reduce their bioavailability, but there seems to be no evidence of a clinically significant interaction in practice.